Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will create an action plan to tackle shortages of pancreatic enzyme replacement therapy drugs.

The Department currently has no plans to convene a roundtable regarding the shortages of pancreatic enzyme replacement therapy (PERT). The Department regularly engages with all suppliers of PERT to discuss the latest stock position and the steps that are being taken to boost production to mitigate the supply issue. Through work with suppliers, we have managed to secure additional volumes of PERT for 2025. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the gap in the market.

The Department also has frequent conversations with representatives from the impacted patient groups so that they are informed on the supply situation and the mitigation actions being taken.

In December 2024, the Department issued further management advice to healthcare professionals. This directs clinicians to consider these unlicensed imports when licensed stock is unavailable, and includes actions for integrated care boards to ensure local mitigation plans are put in place and implemented. The Department, in collaboration with NHS England, has created a webpage to include the latest update on PERT availability and easily accessible advice on the prescribing and ordering of alternative PERT products.